GTBP Sees Strong Bump & Now Breaking News!
GT Biopharma, Inc. (GTBP) saw a strong Wednesday session with a move from under $5 to highs of $6.50. This momentum comes on the heels of (GTBP)’s latest announcement that they will Present Data on Next Generation TriKE (OXS-C3550)! Dr. Jeffrey Miller, Deputy Director of the Masonic Cancer Center, University of Minnesota, will be presenting data on its second-generation anti-CD16-IL-15-anti-CD33 TriKE (OXS-C3550); another first of its kind, single-chain, tri-specific NK cell engager (TriKE). Being that OXS-3550 is expected to enter human clinical trials in 2018, this could be a critical time to be paying close attention to (GTBP)!
Biotech Investors are Hungry for the Next Big Buyout Target
The recent $12 billion acquisition of Kite Pharma, Inc. by big-pharma giant, Gilead Sciences has biotech investors hungry for the next big buyout target.
BIOTECHSTOCKS,.com is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $1,050,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending Nov. 1, 2017 now extended to January 1, 2018 to publicly disseminate information about (GTBP). We own zero shares.